Revealing sit-downs with executives shaping the future of the global mining industry.
Episodes
Thursday Oct 31, 2019
Thursday Oct 31, 2019
The field of precision medicine has latched upon what may well be the Holy Grail in the fight against cancer. When big data are utilized by teams of pathologists, data can be incredibly helpful, but when the right data are comprehensively analyzed by artificial intelligence (AI)-powered models, the data can be downright lifesaving.
Predictive Oncology (NASDAQ: POAI) is in an enviable position in the precision-medicine industry due to its incredibly rich data set of more than 150,000 clinically validated cases on its molecular information platform, with 30,000-plus specific to ovarian cancer. The company is leveraging this unique database through Artificial Intelligence to provide the actionable insights needed to drive pharma R&D programs and improve patient outcomes. A data asset like this typically takes at least five years to fully validate and most competitors are only in the early stages of the process. Predictive Oncology already has it. The uniqueness of its data combined with its proprietary AI platform show true disruptive potential in the field of precision medicine. Leading pharma companies in the space such as Roche Holding AG (OTCQX: RHHBY), GlaxoSmithKline (NYSE: GSK), AstraZeneca (NYSE: AZN) and Bristol-Myers Squibb (NYSE: BMY) have also shown keen interest in the promise of precision medicine and are making multibillion dollar investments in the space.